Montelukast Stada (Montelukast)

Montelukast selectively blocks the CysLT1 receptor, preventing cysteinyl leukotrienes from binding. This inhibition reduces bronchoconstriction, mucus production, and inflammatory cell recruitment in the airways, leading to improved breathing and reduced allergic symptoms.

The appropriate dose of Montelukast Stada is determined by the prescribing healthcare professional based on the patient’s age, condition, and clinical response. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for Montelukast Stada in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against possible risks before prescribing it to pregnant or nursing individuals.

To request Montelukast Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with allergic components or exercise‑related bronchoconstriction, though it may be less potent for acute symptom relief compared with rescue inhalers.

Montelukast Stada should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, direct sunlight and excessive heat to maintain product stability.

Montelukast Stada is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water, following the dosing schedule prescribed by the healthcare professional.

Serious risks include severe allergic reactions such as rash or angioedema, mood alterations like depression or suicidal thoughts, and rare cases of liver injury. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast Stada is contraindicated in individuals with known hypersensitivity to montelukast or any component of the formulation. Caution is advised for patients with a history of severe psychiatric disorders, liver disease, or those taking interacting medications without proper monitoring.